Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PAPA-ARTIS

Financiado

Cerrado

Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging with...

Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging with Minimally Invasive Segmental Artery Coil Embolization A Randomized Controlled Multicentre Trial Chronic aortic aneurysms are permanent and localized dilations of the aorta that remain asymptomatic for long periods of time but continue to increase in diameter before they eventually rupture. Left untreated, the patients’ progn... ver más

30/09/2024

ULEI

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

UNIVERSITAET LEIPZIG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 34 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-09-30

SC1-PM-09-2016: New therapies for chronic diseases

I+D

Cerrada hace 8 años

0% 96% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

34 Participantes

ULEI

2.54M€ | Lider

ARTIS ARQUITECTURA INTERIOR

414.24K€ | Participante

SKANE LAN

221.30K€ | Participante

UNIVERSITATKLINIKUM LEIPZIG

N.D. | Participante

Proyectos interesantes

CUSTOMI Arch

Medical Technol...

Materials Scien...

71K€ Cerrado

aortoseal

Medical Technol...

Biomedical Engi...

6M€ Cerrado

STAAART SmarT Abdominal Aortic AneuRysm Treatment

Medical Technol...

Biomedical Engi...

4M€ Cerrado

OPTAVI

Medical Technol...

Biomedical Engi...

213K€ Cerrado

OXIFLOW

Medical Technol...

Biomedical Engi...

4M€ Cerrado

AORTYX

Medical Technol...

Materials Scien...

71K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 93 meses Fecha Inicio: 2016-12-12
Fecha Fin: 2024-09-30

Líder del proyecto

UNIVERSITAET LEIPZIG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Chronic aortic aneurysms are permanent and localized dilations of the aorta that remain asymptomatic for long periods of time but continue to increase in diameter before they eventually rupture. Left untreated, the patients’ prognosis is dismal, since the internal bleeding of the rupture brings about sudden death. Although successful treatment cures the disease, the risky procedures can result in paraplegia from spinal cord ischaemia or even death, particularly for aneurysms extending from the thoracic to the abdominal aorta and thus involving many segmental arteries to the spinal cord, i.e. thoracoabdominal aortic aneurysms of Crawford type II. Although various strategies have achieved a remarkable decrease in the incidence of paraplegia, it is still no less than 10 to 20%. However, it has been found that the deliberate occlusion of the segmental arteries to the paraspinous collateral network finally supplying the spinal cord does not increase rates of permanent paraplegia. A therapeutic option, ‘minimally invasive segmental artery coil embolization’ has been devised which proceeds in a ‘staged’ way to occlude groups of arteries under highly controlled conditions after which time must be allowed for arteriogenesis to build a robust collateral blood supply. PAPA-ARTiS is a phase II trial to demonstrate that a staged treatment approach can reduce paraplegia and mortality dramatically. It can be expected to have both a dramatic impact on the individual patient's quality of life if saved from a wheelchair, and also upon financial systems through savings in; 1) lower costs in EU health care; 2) lower pay-outs in disability insurance (est. at 500k in Year 1), and; 3) loss of economic output from unemployment. Approx. 2500 patients a year in Europe undergo these high risk operations with a cumulative paraplegia rate of over 15%; therefore >100M per year in costs can be avoided and significantly more considering the expected elimination of type II endoleaks.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores